Prior to joining Geron, Dr. Scarlett served as a director of CytomX Therapeutics, Inc., a biopharmaceutical company focused on developing antibody therapeutics for the treatment of cancer, from June 2016 to June 2022. He was also a director for Chiasma, Inc., a biopharmaceutical company focused on transforming injectable drugs into oral medications, from February 2015 until its acquisition by Amyrt Pharma plc, a biopharmaceutical company, in August 2021. Dr. Scarlett served as President, Chief Executive Officer and a member of the board of directors of Proteolix, Inc., a privately held, oncology-oriented biopharmaceutical company, from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc., an oncology-oriented biopharmaceutical company, in November 2009. From February 2002 until its acquisition by Ipsen, S.A. in October 2008, Dr. Scarlett served as the Chief Executive Officer and a member of the board of directors of Tercica, Inc., an endocrinology-oriented biopharmaceutical company, and as its President from February 2002 through February 2007.
From March 1993 to May 2001, Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation. In 1995, he co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical manufacturing operation, and served as a member of its board of directors from inception to 2000. From 1991 to 1993, Dr. Scarlett headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk Pharmaceuticals, Inc., a wholly owned subsidiary of Novo Nordisk A/S. Dr. Scarlett received his B.A. degree in chemistry from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine.
What is John A. Scarlett's net worth?
The estimated net worth of John A. Scarlett is at least $15,875.00 as of February 27th, 2025. Dr. Scarlett owns 12,500 shares of Geron stock worth more than $15,875 as of April 20th. This net worth approximation does not reflect any other investments that Dr. Scarlett may own. Additionally, Dr. Scarlett receives a salary of $1,360,000.00 as CEO at Geron. Learn More about John A. Scarlett's net worth.
How old is John A. Scarlett?
What is John A. Scarlett's salary?
How do I contact John A. Scarlett?
The corporate mailing address for Dr. Scarlett and other Geron executives is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. Geron can also be reached via phone at (650) 473-7700 and via email at investor@geron.com. Learn More on John A. Scarlett's contact information.
Has John A. Scarlett been buying or selling shares of Geron?
John A. Scarlett has not been actively trading shares of Geron within the last three months. Most recently, on Thursday, February 27th, John A. Scarlett bought 12,500 shares of Geron stock. The stock was acquired at an average cost of $1.76 per share, with a total value of $22,000.00. Following the completion of the transaction, the chief executive officer now directly owns 12,500 shares of the company's stock, valued at $22,000. Learn More on John A. Scarlett's trading history.
Who are Geron's active insiders?
Geron's insider roster includes Faye Feller (Executive Vice President, Chief Medical Officer), Andrew Grethlein (xecutive Vice President, Chief Operating Officer), V. Lawlis (Director), Susan Molineaux (Director), Elizabeth O'Farrell (Director), Scott Samuels (Executive Vice President, Chief Legal Officer and Secretary), John Scarlett (CEO), and Robert Spiegel (Director). Learn More on Geron's active insiders.
Are insiders buying or selling shares of Geron?
During the last twelve months, Geron insiders bought shares 2 times. They purchased a total of 27,500 shares worth more than $46,150.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 1,562,248 shares worth more than $6,808,003.88. The most recent insider tranaction occured on February, 27th when EVP Scott Alan Samuels bought 15,000 shares worth more than $24,150.00. Insiders at Geron own 3.1% of the company.
Learn More about insider trades at Geron. Information on this page was last updated on 2/27/2025.
